Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction

Antiviral Research

Volumn 69, Issue 2, 2006, Pages 70-76

  Ho, Tin Yun ^a   Wu, Shih Lu ^a   Chen, Jaw Chyun ^a   Wei, Yen Chiao ^a   Cheng, Shin Ei ^a   Chang, Yung Hsien ^a   Liu, Hsu Jan ^a   Hsiang, Chien Yun ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Angiotensin converting enzyme 2; Peptide; Pseudovirus; SARS CoV; Spike protein; Vero E6 cells

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; PROTEIN INHIBITOR; RECOMBINANT PROTEIN;

ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; BIOTINYLATION; CONTROLLED STUDY; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN INTERACTION; RECEPTOR BINDING; RETROVIRUS; SARS CORONAVIRUS; VERO CELL; VIRUS INFECTIVITY;

AMINO ACID SEQUENCE; ANIMALS; BIOTINYLATION; CERCOPITHECUS AETHIOPS; DNA-BINDING PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; PEPTIDES; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE PROTEINS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TRANSCRIPTION FACTORS; VERO CELLS; VIRAL ENVELOPE PROTEINS;

ANIMALIA; CORONAVIRUS; SARS CORONAVIRUS; SPIROPLASMA PHAGE 4;

EID: 31444441306     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2005.10.005     Document Type: Article

References (38)

1. G.J. Babcock, D.J. Esshaki, W.D. Thomas, and D.M. Ambrosino Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor J. Virol. 78 2004 4552 4560
2. B.J. Bosch, R. van der Zee, C.A. de Haan, and P.J. Rottier The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex J. Virol. 77 2003 8801 8811
3. S. Chakraborti, P. Prabakaran, X. Xiao, and D.S. Dimitrov The SARS coronavirus glycoprotein receptor binding domain: fine mapping and functional characterization Virol. J. 2 2005 73 82
4. Z. Chen, L. Zhang, C. Qin, L. Ba, C.E. Yi, F. Zhang, Q. Wei, T. He, W. Yu, J. Yu, H. Gao, X. Tu, A. Gettie, M. Farzan, K.Y. Yuen, and D.D. Ho Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region J. Virol. 79 2005 2678 2688
5. P.Y. Chou, and G.D. Fasman Prediction of the secondary structure of proteins from their amino acid sequence Adv. Enzymol. Relat. Areas Mol. Biol. 47 1978 45 148
6. E. DeClercq New developments in anti-HIV chemotherapy Curr. Med. Chem. 8 2001 1543 1572
7. D.S. Dimitrov Virus entry: molecular mechanisms and biomedical application Nat. Rev. Microbiol. 2 2004 109 122
8. C. Drosten, S. Gunther, W. Preiser, S. van der Werf, H.R. Brodt, S. Becker, H. Rabenau, M. Panning, L. Kolesnikova, R.A. Fouchier, A. Berger, A.M. Burguiere, J. Cinatl, M. Eickmann, N. Escriou, K. Grywna, S. Kramme, J.C. Manuguerra, S. Muller, V. Rickerts, M. Sturmer, S. Vieth, H.D. Klenk, A.D. Osterhaus, H. Schmitz, and H.W. Doerr Identification of a novel coronavirus in patients with severe acute respiratory syndrome N. Engl. J. Med. 348 2003 1967 1976
9. E.A. Emini, J.V. Hughes, D.S. Perlow, and J. Boger Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide J. Virol. 55 1985 836 839
10. R.A. Fouchier, T. Kuiken, M. Schutten, G. van Amerongen, G.J.J. van Doornum, B.G. van den Hoogen, M. Peiris, W. Lim, K. Stohr, and A.D.M.E. Osterhaus Koch's postulates fulfilled for SARS virus Nature 423 2003 240
11. T.Y. Ho, S.L. Wu, S.E. Cheng, Y.C. Wei, S.P. Huang, and C.Y. Hsiang Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein Biochem. Biophys. Res. Commun. 313 2004 938 947
12. H. Hofmann, K. Hattermann, A. Marzi, T. Gramberg, M. Geiner, M. Krumbiegel, S. Kuate, K. Uberla, M. Niedrig, and S.H. Pohlmann S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients J. Virol. 78 2004 6134 6142
13. H. Hofmann, M. Geier, A. Marzi, M. Krumbiegel, M. Peipp, G.H. Fey, T. Gramberg, and S. Pohlmann Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor Biochem. Biophys. Res. Commun. 319 2004 1216 1221
14. C.Y. Hsiang, S.L. Wu, and T.Y. Ho Morin inhibited 12-O- tetradecanoylphorbol-13-acetate-induced hepatocellular transformation via activator protein 1 signaling pathway and cell cycle progression Biochem. Pharmcol. 69 2005 1603 1611
15. P.A. Karplus, and G.E. Schulz Prediction of chain flexibility in proteins. A tool for the selection of peptide antigens Naturwisenschaften 72 1985 212 213
16. C.T. Keng, A. Zhang, S. Shen, K.M. Lip, B.C. Fielding, T.H. Tan, C.F. Chou, C.B. Loh, S. Wang, J. Fu, X. Yang, S.G. Lim, W. Hong, and Y.J. Tan Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents J. Virol. 79 2005 3289 3296
17. J.M. Kilby, S. Hopkins, T.M. Venetta, B. DiMassimo, G.A. Cloud, J.Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M.R. Johnson, M.A. Nowak, G.M. Shaw, and M.S. Saag Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry Nat. Med. 4 1998 1302 1307
18. T.G. Ksiazek, D. Erdman, C.S. Goldsmith, S.R. Zaki, T. Peret, S. Emery, S. Tong, J.A. Comer, W. Lim, P.E. Rollin, S.F. Dowell, A. Ling, C.D. Humphrey, W. Shieh, J. Guarner, C.D. Paddock, P. Rota, B. Fields, J. DeRisi, J. Yang, N. Cox, J.M. Hughes, J.W. LeDuc, W.J. Bellini, and L.J. Anderson A novel coronavirus associated with severe acute respiratory syndrome N. Engl. J. Med. 348 1953-1966
19. J. Kyte, and R.F. Doolittle A simple method for displaying the hydropathic character of a protein J. Mol. Biol. 157 1982 105 132
20. W. Li, M.J. Moore, N. Vasilieva, J. Sui, S.K. Wong, M.A. Berne, M. Somasundaran, J.L. Sullivan, K. Luzuriaga, T.C. Greenough, H. Choe, and M. Farzan Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus Nature 426 2003 450 454
21. W. Li, C. Zhang, J. Sui, J.H. Kuhn, M.J. Moore, S. Luo, S.K. Wong, I.C. Huang, K. Xu, N. Vasilieva, A. Murakami, Y. He, W.A. Marasco, Y. Guan, H. Choe, and M. Farzan Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2 EMBO J. 24 2005 1634 1643
22. S. Liu, G. Xiao, Y. Chen, Y. He, J. Niu, C.R. Escalante, H. Xiong, J. Farmar, A.K. Debnath, P. Tien, and S. Jiang Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors Lancet 363 2004 938 947
23. J. Ma, S. Kennedy-Stoskopf, J.M. Jaynes, L.M. Thurmond, and W.A. Tompkins Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro J. Virol. 76 2002 9952 9961
24. M.A. Marra, S.J. Jones, C.R. Astell, R.A. Holt, A. Brooks-Wilson, Y.S. Butterfield, J. Khattra, J.K. Asano, S.A. Barber, S.Y. Chan, A. Cloutier, S.M. Coughlin, D. Freeman, N. Girn, O.L. Griffith, S.R. Leach, M. Mayo, H. McDonald, S.B. Montgomery, P.K. Pandoh, A.S. Petrescu, A.G. Robertson, J.E. Schein, A. Siddiqui, D.E. Smailus, J.M. Stott, G.S. Yang, F. Plummer, A. Andonov, H. Artsob, N. Bastien, K. Bernard, T.F. Booth, D. Bowness, M. Czub, M. Drebot, L. Fernando, R. Flick, M. Garbutt, M. Gray, A. Grolla, S. Jones, H. Feldmann, A. Meyers, A. Kabani, Y. Li, S. Normand, U. Stroher, G.A. Tipples, S. Tyler, R. Vogrig, D. Ward, B. Watson, R.C. Brunham, M. Krajden, M. Petric, D.M. Skowronski, C. Upton, and R.L. Roper The Genome sequence of the SARS-associated coronavirus Science 300 2003 1399 1404
25. M.J. Moore, T. Dorfman, W. Li, S.K. Wong, Y. Li, J.H. Kuhn, J. Coderre, N. Vasilieva, Z. Han, T.C. Greenough, M. Farzan, and H. Choe Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2 J. Virol. 78 2004 10628 10635
26. L. Ni, J. Zhu, J. Zhang, M. Yan, G.F. Gao, and P. Tien Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain Biochem. Biophys. Res. Commun. 330 2005 39 45
27. J.S.M. Peiris, S.T. Lai, L.L.M. Poon, Y. Guan, L.Y.C. Yam, W. Lim, J. Nicholls, W.K.S. Yee, W.W. Yan, M.T. Cheung, V.C.C. Cheng, K.H. Chan, D.N.S. Tsang, R.W.H. Yung, T.K. Ng, K.Y. Yuen members of the SARS study group Coronavirus as a possible cause of severe acute respiratory syndrome Lancet 361 2003 1319 1325
28. J.D. Pinon, S.M. Kelly, N.C. Price, J.U. Flanagan, and D.W. Brighty An antiviral peptide targets a coiled-coil domain of the human T-cell leukemia virus envelope glycoprotein J. Virol. 77 2003 3281 3290
29. P.A. Rota, M.S. Oberste, S.S. Monroe, W.A. Nix, R. Campagnoli, J.P. Icenogle, S. Penaranda, B. Bankamp, K. Maher, M.H. Chen, S. Tong, A. Tamin, L. Lowe, M. Frace, J.L. DeRisi, Q. Chen, D. Wang, D.D. Erdman, T.C. Peret, C. Burns, T.G. Ksiazek, P.E. Rollin, A. Sanchez, S. Liffick, B. Holloway, J. Limor, K. McCaustland, M. Olsen-Rasmussen, R. Fouchier, S. Gunther, A.D. Osterhaus, C. Drosten, M.A. Pallansch, L.J. Anderson, and W.J. Bellini Characterization of a novel coronavirus associated with severe acute respiratory syndrome Science 300 2003 1394 1399
30. J. Sui, W. Li, A. Murakami, A. Tamin, L.J. Matthews, S.K. Wong, M.J. Moore, A.S. Tallarico, M. Olurinde, H. Choe, L.J. Anderson, W.J. Bellini, M. Farzan, and W.A. Marasco Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association Proc. Natl. Acad. Sci. U.S.A. 101 2004 2536 2541
31. J. Sui, W. Li, A. Roberts, L.J. Mattews, A. Murakami, L. Vogel, S.K. Wong, K. Subbarao, M. Farzan, and W.A. Marasco Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acure respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants J. Virol. 79 2005 5900 5906
32. B. Tripet, M.W. Howard, M. Jobling, R.K. Holmes, K.V. Holmes, and R.S.B. Hodges Structural characterization of the SARS-coronavirus spike S fusion protein core J. Biol. Chem. 279 2004 20836 20849
33. S.E. van Compernolle, A.V. Wiznycia, J.R. Rush, M. Dhanasekaran, P.W. Baures, and S.C. Todd Small molecule inhibition of hepatitis C virus E2 binding to CD81 Virology 314 2003 371 380
34. S.K. Wong, W. Li, M.J. Moore, H. Choe, and M. Farzan A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2 J. Biol. Chem. 279 2004 3197 3201
35. X.D. Wu, B. Shang, R.F. Yang, H. Yu, Z.H. Ma, X. Shen, Y.Y. Ji, Y. Lin, Y.D. Wu, G.M. Lin, L. Tian, X.Q. Gan, S. Yang, W.H. Jiang, E.H. Dai, X.Y. Wang, H.L. Jiang, Y.H. Xie, X.L. Zhu, G. Pei, L. Li, J.R. Wu, and B. Sun The spike protein of severe acute respiratory syndrome (SARS) is cleaved in virus infected Vero-E6 cells Cell Res. 14 2004 400 406
36. X. Xiao, S. Chakraborti, A.S. Dimitrov, K. Gramatikoff, and D.S. Dimitrov The SARS-CoV S glycoprotein: expression and functional characterization Biochem. Biophys. Res. Commun. 312 2003 1159 1164
37. K. Yuan, L. Yi, J. Chen, X. Qu, T. Qing, X. Rao, P. Jiang, J. Hu, Z. Xiong, Y. Nie, X. Shi, W. Wang, C. Ling, X. Yin, K. Fan, L. Lai, M. Ding, and H. Deng Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein Biochem. Biophys. Res. Commun. 319 2004 746 752
38. J. Zhu, G. Xiao, Y. Xu, F. Yuan, C. Zheng, Y. Liu, H. Yan, D.K. Cole, J.I. Bell, Z. Rao, P. Tien, and G.F. Gao Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors Biochem. Biophys. Res. Commun. 319 2004 283 288